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Abstract: Purine nucleoside phosphorylase (PNP) is an essential enzyme in the purine salvage pathway of Helicobacter pylori. Since H. pylori 
lacks the ability to synthesize purine nucleosides de novo, inhibition of this enzyme could stop the growth of this bacterium. However, for the 
design of successful inhibitors the details of the mechanism of this enzyme should be fully understood. PNPs catalyze cleavage of the glycosidic 
bond of purine nucleosides, and phosphate is one of the substrates. It is thought that binding of phosphate induces the conformational change 
as a necessary initial step in the catalysis. This conformational change is manifested in closing of either one of the six active sites in the 
homohexameric PNPs. It is unclear whether the binding of phosphate is sufficient or just a necessary condition for the closing of the active site. 
In this paper we conducted an experiment to check this by soaking the crystals of the apo form of the enzyme in increasing concentrations of 
phosphate. 
 





UCCESSFUL design of enzyme inhibitors, and therefore 
also of prospective drugs, requires a detailed know-
ledge of their mechanism of action. This becomes even 
more important when the enzyme in question, purine 
nucleoside phosphorylase (PNP), is an attractive drug 
target from Helicobacter pylori, one of the pathogens that 
represents a very serious threat to human health.[1] 
Although much progress has been made over the years of 
our research on PNP from E. coli, the complete blueprint of 
the catalytic mechanism of PNP is yet to be drawn.[2–8] 
What makes PNP an attractive target for the fight against 
this severe pathogen is the fact that this bacterium relies 
exclusively on the purine salvage pathway for the synthesis 
of purine nucleosides, and in this pathway the PNP plays a 
key role.[9] For that reason inhibiting this enzyme would cut 
down the only source of nucleosides and ultimately would 
lead to its eradication.  
 The PNPs in bacteria are predominantly homo-
hexamers, although there are also trimeric ones.[10] Each 
monomer in H. pylori is 237 amino acids in length.[5] Each 
monomer pairs up with one of its neighbors by mutually 
completing the active sites with two amino acids (His4 and 
Arg43, Figure 1a). This pair of monomers forms a dimer via 
an approximate two-fold rotation symmetry. The complete 
hexamer is then formed by three-fold rotation of the 
dimers, thus making a hexamer with an approximate 32 
point group symmetry (Figure 1b). 
 The reaction that PNP catalyzes is the cleavage of the 
glycosidic bond of purine (2'-deoxy)nucleosides, leading to 
free base and (2'-deoxy)ribose-1-phosphate as products. 
Therefore it requires phosphate as one of its substrates. In 
addition to its role as a substrate, phosphate also initiates 
the conformational change that is necessary for the 
catalysis. Namely, binding of phosphate induces a 
segmentation of the helix H8 located at the entrance to the 
active site.[2] The segmentation of the helix H8 occurs at the 
amino acid Phe221 and a smaller part of that helix moves 
towards the active site. This makes the active site less 
accessible from the outside and is known as closed 
conformation (Figure 2). The movement of the segmented 
part of the H8 helix is necessary to bring the side chain of 
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the catalysis.[6] This initial step in the catalysis has been 
confirmed by kinetic and mutation studies.[2] 
 However, the active sites in PNP do not open and 
close independently. Namely, closing of the active site is 
connected to other sites by negative cooperativity, which 
means that closing of one active site makes it more difficult 
for the other active sites to close.[6] The mechanism by 
which this cooperativity is realized is yet unclear. It is not 
known whether this occurs primarily between the 
monomers in a single dimer, or is it also the case between 
the monomers from different dimers. In a recent survey of 
various possible configurations of open and closed active 
sites in all the determined crystal structures of PNPs from 
different organisms, quite a number of possibilities was 
found,[8] and PNP from H. pylori even shows some 
previously unknown ones.[7] 
 In an attempt to isolate the event of phosphate 
binding to an apo form of PNP we have considered an 
experiment where all the spurious factors that could 
influence this binding are minimized. Specifically, to 
eliminate all the different conditions that could affect the 
phosphate binding, the crystals of the apo form of the 
enzyme were soaked in different concentrations of 
phosphate. For this reason, this was done using the crystals 
from the very same crystallization drop. We have tried to 
scan wide range of phosphate concentrations (varying two 
orders in magnitude), trying not only to the get binding of 
phosphate, but also to establish the order in which the 
active sites were populated.  
 
EXPERIMENTAL SECTION 
Cloning, Expression and Purification of 
PNP from H. pylori 
H. pylori strain ATCC 26695 genomic DNA was obtained 
from the Department of Bacterial Genetics, Institute of 
Microbiology, Faculty of Biology, University of Warsaw. As 
described before for the PNP from clinical isolate of H. 
pylori,[5] deoD gene was cloned into pET21b expression 
vector (Invitrogen, Germany). The DNA sequence of deoD 
gene from H. pylori was confirmed by sequence analysis 
(Macrogen, Netherlands). 
 For the expression of PNP from H. pylori (HpPNP), 
the constructed plasmid pET21b-HPdeoD was subcloned 
into E. coli cell strain BL21-CodonPlus(DE3)-RIL (Agilent, 
US). The expression of PNP was performed essentially as 
described before.[8] 
 
Figure 2. Overlap of the open and closed conformation of 
one monomer of PNP from H. pylori (PDB code: 5MX4).[5] It 
can be seen that majority of the monomer stays exactly the 
same, and the segmentation of the helix H8 partially closes 
the active site. The binding of phosphate and its position are 
drawn schematically. 
  
Figure 1. The overall architecture of the PNP from H. pylori 
hexamer (PDB code: 6G7X). a) Individual monomers join 
together to form dimers with two-fold symmetry axis. Each 
monomer completes the active site of the other monomer 
in the dimer by donating two amino acids, His4 and Arg43. 
b) Three such dimers are joined together by three-fold 
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 Two-step purification (anion exchange and affinity 
chromatography) of overexpressed protein was performed 
as described previously.[5] The activity assay using N(7)-
methylguanosine as a substrate[5] and the protein 
concentration assay using the method of Bradford[11] with 
bovine serum albumin as a standard were used for 
following the purification procedure. For purified HpPNP, 
protein concentration was determined from UV spectra 
using the molar extinction coefficient (calculated from the 
amino acid sequence)[12] at 280 nm ε = 13410 mol–1 L cm–1. 
Protein purity was confirmed by SDS-PAGE on PhastSystem 
(GE Healthcare, UK) in 12.5 % acrylamide.  
Crystallization, Data Collection and 
Structure Determination 
Crystals suitable for X-ray diffraction were grown in 
crystallization conditions containing 0.2 mol L–1 imidazole, 
40 % (w/v) polypropylene glycol (PPG) 400 and 0.02 %  
NaN3, pH = 7.0 (conditions B7 from MIDAS screen, Molecular 
dimensions, Newmarket, UK). Crystallization was carried 
out by means of a vapor diffusion method in a hanging 
drop setup, where the wells contained 700 μL of the 
crystallization solution, and the drops contained 1 μL of 
purified protein mixed with 1 μL of crystallization solution. 
One series of crystallization contained 12 wells wherein the 
concentration of the PNP protein used was 11.61 mg mL–1. 
The second series of crystallization contained 8 wells 
wherein the concentration of the PNP used was 14.49 mg 
mL–1. Both plates were set up at 18 °C. For the soaking of 
crystals the solutions of phosphate in crystallization 
conditions were prepared. The final phosphate 
concentrations were: 100 mmol L–1, 50 mmol L–1, 25 mmol 
L–1, 12.5 mmol L–1, 6.25 mmol L–1, 3.125 mmol L–1, 1.56 
mmol L–1 and 0.78 mmol L–1. 
 Protein crystals were soaked in two ways. One way 
was to transfer the crystal from the crystallization drop to 
0.5 μL drop of phosphate solution, soak it for one minute 
and then freeze it in liquid nitrogen. The second way 
involved the addition of 0.5 μL of phosphate solution to the 
original crystallization drop, starting with the lowest 
concentration and fishing one crystal one minute after each 
new addition. Data collection on around twenty crystals 
from different phosphate concentrations was done at the 
XRD1 beamline of the Elettra synchrotron, Trieste, Italy 
using the Dectris Pilatus 2M detector. The data collection 
and refinement parameters for the structure described 
here are summarized in Table 1. The data was integrated 
using the XDS program.[13] The structure was solved by 
molecular replacement using the Molrep program[14] and 
using the structure of HpPNP apo structure as a model (PDB 
code 6F52).[7] The refinement of the structure was carried 
out using the phenix.refine routine from the Phenix 
package.[15] The atomic coordinates and structure factors 
have been deposited in the Protein Data Bank: with 
accession code 6G7X.  
 
RESULTS AND DISCUSSION 
Although more than twenty datasets were collected at the 
synchrotron beamline, only a single crystal structure was 
determined. Most of the crystals diffracted to satisfactory 
resolution of around 2–2.5 Å, but showed very high 
mosaicity, pseudo-symmetry and/or twinning related 
pathologies. It was very difficult to index the reflections and 
Table 1. Data collection and refinement statistics for the 
monoclinic structure. 
Wavelength (Å) 1.0 
Resolution range 46.7 – 1.8 (1.82 – 1.76)(a) 
Space group P21 
Unit cell 
a, b, c, (Å)  
β (°) 
 
93.3, 91.5, 93.4  
119.9 
Total reflections 829920 
Unique reflections 133850 (13061) 
Multiplicity 6.2 
Completeness (%) 99.7 
Mean I/sigma(I) 12.9 
Wilson B-factor 13.60 
Rmerge 0.09 
Refinement  
Reflections used in refinement 133826 (13058) 
Reflections used for R-free 1986 (186) 
Rwork 0.15 (0.21) 
Rfree 0.19 (0.25) 
Number of non-hydrogen atoms 12053 
   macromolecules 10881 
   ligands 145 
Protein residues 1398 
RMS(bonds) 0.029 
RMS(angles) 0.81 
Ramachandran favoured (%) 96.8 
Ramachandran allowed (%) 3.2 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 0.67 
Clash score 4.76 
Average B-factor 18.97 
   macromolecules 18.03 
   ligands 31.10 
   solvent 27.16 
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to integrate the data. In few of the cases two space groups 
were identified: a triclinic one in the space group P1 with 
unit cell a = 93.3 Å, b = 93.3 Å, c = 95.3 Å, α = 92.6 °, β = 97.9 ° 
and γ = 120.1 °, and a monoclinic one in the space group C2 
with unit cell a = 162.1 Å, b = 93.5 Å and c = 96.1 Å with β = 
100.4 °. The triclinic structure has two hexamers and the 
monoclinic structure one PNP hexamer in the asymmetric 
unit. Although the space groups are different both of the 
crystal packings are actually analogous. Namely, hexamers 
pack next to each other in a planar arrangement that is very 
approximately hexagonal (Figure 3). This is facilitated by 
their shape that is roughly hexagonal. This planar 
arrangement is parallel to ab plane in the triclinic case 
(which makes the angle γ very nearly equal to 120 °), and 
also parallel to ab plane in the monoclinic case where the 
ratio of a : b = 162.1 : 93.5 ~ 3  makes the centered rectan-
gular lattice close to hexagonal. The 3D-structure in both 
space groups is then realized by stacking of this planar 
almost hexagonal arrangements on top of each other 
(Figure 3). The difference between the structures arises 
from the shear direction and shear angle of stacking 
between these planes. It is quite conceivable that the 
relatively poor quality of these crystals is related to the 
existence of a number of possible directions into which 
these planes can move with respect to each other (in a 
manner somewhat reminiscent of a graphite structure).  
 The single structure that gave rise to very good 
diffraction data was the one obtained with the crystal that 
was fished from the crystallization drop where the 
phosphate was added in 6 steps. The crystal spent 
approximately 2 hours in the crystallization drop where the 
final concentration of phosphate was 12.3 mmol L–1. This 
structure crystallized in a monoclinic space group P21 with 
unit cell a = 93.3 Å, b = 91.5 Å and c = 93.4 Å with β = 119.9 °. 
Details on the crystal structure and refinement are given in 
Table 1. What can be noted immediately is the similarity of 
the unit cell to the triclinic structure. In fact, this structure 
is also isomorphic to the previously described two 
structures in the sense that the packing in the crystal is 
realized as the stacking of hexagonal layers. However, as 
the data in Table 1 confirms, in this case there is no trace of 
crystal pathologies that were noted in the other structures. 
This could be the result of longer time that the crystal spent 
in the soaking solution (2 hours compared to only a 1 
minute that the other crystals were soaked), as the crystals 
had more time to reorder the internal structure which 
resulted in very good quality of diffraction. 
 The electron density of the six active sites in the 
crystal structure reflects the high quality of the dataset 
(Figure 4). In all six active sites the electron density shows 
the presence of two imidazole molecules which come from 
the crystallization solution. They occupy the base binding 
 
 
Figure 3. Triclinic P1 in a) and monoclinic C2 forms in b) of 
PNP that lead to problematic diffraction datasets. It is clear 
that irrespective of the different space groups the packing 
is quite analogous. The hexamers of PNP pack in the 
approximate planar hexagonal arrangement. The full crystal 
packing is formed by stacking such planar layers on top of 
each other (bottom). Different space groups arise by 
changing the shear angle and direction of the stacking. It is 
possible that energetic barrier of movement of the layers is 
relatively low and is causing the disorder which in turn 




Figure 4. Active sites in all six monomers of PNP given in 
approximately equal orientation. Electron density is shown 
(blue is 2mFo-DFc map contoured at 1σ level, green and red 
are mFo-DFc map at +3σ and -3σ levels respectively). In the 
centre of each panel the phosphate molecules are visible in 
the map, although not at full occupancy. To the left of each 
phosphate two molecules of imidazole are visible which are 
bound in the base binding part of the active site. To the right 
of each phosphate around Cys19 there is some residual 
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part of the active site. Most importantly, the phosphate 
molecules are visible in the electron density in all six active 
sites. The occupancies of phosphates are partial, ranging 
from 0.52 in active site B to 0.64 in active site C. This is in 
line with generally weaker binding of phosphate to HpPNP 
compared to e.g. E. coli PNP.[7] However, somewhat 
surprisingly, none of the active sites have closed upon 
phosphate binding, i.e. all the helices H8 in each monomer 
remained unsegmented. This shows that binding of 
phosphate alone is not enough to provoke the closing of 
the active site. One can speculate on the reasons for this in 
view of the simplest possible setup of this experiment, 
where the crystals which initially contained no phosphate 
in the active site, were soaked in phosphate and it was 
detected in the active site, but it did not cause the closing 
of at least some active sites. The reason could lie in 
insufficient concentration of phosphate that resulted in 
only partial binding and did not trigger the closing. 
Furthermore, the influence of two imidazole molecules as 
well as the oxidation of Cys19 in the close proximity to 
phosphate may also be important (Figure 4). But it could 
also be a genuine feature of H. pylori PNP that perhaps 
behaves differently than PNPs from other organisms, most 
notably from E. coli PNP. Finally, it may have to do with the 
complexity of the enzyme mechanism as such, which 
requires other factors to proceed besides phosphate, such 
as presence of its other substrate. Also, complex and yet 
poorly understood cooperativity between monomers has 
to be kept in mind.  
 In summary, the present work demonstrates, at least 
in the crystal form and considering that many external 
factors influencing phosphate binding have been 
minimized, that the binding of phosphate to the active site 
of PNP from H. pylori does not cause the conformational 
change by itself, thus only adding another piece to the 
puzzle of the sophisticated catalytic mechanism and 
complex cooperation between subunits of PNPs.  
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